author-photo

Kenjiro Aogi

237

Papers

3620

Citations

Citation Trend

Filter By

Papers (163) Sort By

Journal Conference Others

Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer.

2021 Acta Medica Okayama
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS12-10: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Factors associated with return to work of breast cancer patients following axillary lymph node dissection.

2021 Work-a Journal of Prevention Assessment & Rehabilitation
Show All
- Source
- Cite
- Save
Citations (0)
Investigation of Factors Affecting Early Quality of Life of Patients after Breast Cancer Surgery.

2021 Healthcare
Show All
- Source
- Cite
- Save
Citations (0)
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective

2021 Case Reports in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers.

2021 Surgical Case Reports
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (2)